EUVIMEDEUVIMED entdecken
Kohortenstudie

Concomitant IVIG and intermediate-dose methylprednisolone in critically ill patients with severe COVID-19: a retrospective cohort study

Dursun Elmas, Muhammet Cemal Kızılarslanoğlu

Journal of Health Sciences and Medicine · 20.07.2026 · 9 (4) · 906-916

DOI: 10.32322/jhsm.1937161 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Health Sciences and Medicine, online erschienen am 20.07.2026. Verfasst von Dursun Elmas und 1 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Gefördert von: none.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Severe COVID-19 pneumonia with acute respiratory distress syndrome (ARDS) continues to carry high mortality in critically ill patients. During the pre-dexamethasone era, various immunomodulatory strategies were explored. We investigated whether early concomitant intravenous immunoglobulin (IVIG) and intermediate-dose methylprednisolone improved outcomes in ICU patients with severe COVID-19.

Methods

Single-centre retrospective cohort study (30 March-14 November 2020) of 178 critically ill adults with laboratory-confirmed severe COVID-19. Eighty-eight patients received IVIG (400 mg/kg/day ×5 days) plus intermediate-dose methylprednisolone (250 mg/day ×5 days) within 7 days of ICU admission in addition to early-pandemic background therapy; 90 patients received background therapy alone. Combination therapy was modelled as a time-dependent covariate in an extended Cox model (primary analysis) with 7-day landmark sensitivity analysis. The primary outcome was in-hospital mortality.

Results

Combination therapy was initiated at a median of 4 (IQR 3-6) days after ICU admission. In-hospital mortality was 30.7% in the combination group versus 81.1% in the control group. After multivariable adjustment, combination therapy was independently associated with substantially lower mortality (time-dependent adjusted HR 0.39, 95% CI 0.22-0.68; p60% relative reduction in mortality without evidence of harm. Prospective randomised trials are warranted.

Förderung

  • none

Zitieren

APA

Elmas, D., & Kızılarslanoğlu, M. C. (2026). Concomitant IVIG and intermediate-dose methylprednisolone in critically ill patients with severe COVID-19: a retrospective cohort study. Journal of Health Sciences and Medicine, 9(4), 906-916. https://doi.org/10.32322/jhsm.1937161

Vancouver

Elmas D, Kızılarslanoğlu MC. Concomitant IVIG and intermediate-dose methylprednisolone in critically ill patients with severe COVID-19: a retrospective cohort study. Journal of Health Sciences and Medicine. 2026;9(4):906-916. doi:10.32322/jhsm.1937161

BibTeX
@article{Elmas2026,
  author = {Elmas, Dursun and Kızılarslanoğlu, Muhammet Cemal},
  title = {Concomitant IVIG and intermediate-dose methylprednisolone in critically ill patients with severe COVID-19: a retrospective cohort study},
  journal = {Journal of Health Sciences and Medicine},
  year = {2026},
  volume = {9},
  number = {4},
  pages = {906--916},
  doi = {10.32322/jhsm.1937161}
}
Kostenlos starten →